This process was blunted by anti-CXCL9 and anti-CXCR3 antibodies, suggesting that the CXCR3-CXCL9/10 axis plays a crucial role in this step of cancer dissemination, with further studies demonstrating that CXCL10/CXCR3 co-expression is associated with early metastatic disease progression and poor overall survival [45,48]. The gene discussed is CXCL9; the disease is cancer.